Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;18(3):233-9.
doi: 10.4196/kjpp.2014.18.3.233. Epub 2014 Jun 12.

Hypericum Perforatum Decreased Hippocampus TNF-α and Corticosterone Levels with No Effect on Kynurenine/Tryptophan Ratio in Bilateral Ovariectomized Rats

Affiliations

Hypericum Perforatum Decreased Hippocampus TNF-α and Corticosterone Levels with No Effect on Kynurenine/Tryptophan Ratio in Bilateral Ovariectomized Rats

Wesam M El-Bakly et al. Korean J Physiol Pharmacol. 2014 Jun.

Abstract

The present study was designed to investigate the effect Hypericum Perforatum (HP), on behavioral changes, corticosterone, TNF-α levels and tryptophan metabolism and disposition in bilateral ovariectomized rats compared to 17α -ethinylestradiol. Behavioral analysis by measuring immobility time in forced swimming test and open field test, serum and hippocampal corticosterone and TNF-α along with hippocampal kynurenine/tryptophan ratio were determined in mature ovariectomized rats treated orally either by HP at three different doses 125, 250, and 500 mg/kg/day or by 17α-ethinylestradiol 30 µg/kg/day for 30 days. Ovariectomized rats showed significant increase in immobility time in the forced swimming test. Along with elevation in serum and hippocampal TNF-α and corticosterone levels associated with significant increase in hippocampal kynurenine/tryptophan ratio. Immobility time in the forced swimming test was decreased in rats treated by different doses of HP in a dose dependent manner and 17α-ethinylestradiol with no concomitant changes in the open field test. Only Rats treated with HP exhibited significant decrease in the elevated serum and hippocampal TNF-α and corticosterone, which couldn't explain the associated insignificant effect on hippocampaus kynurenine/tryptophan ratio in comparison to ovariectomized untreated rats. It is concluded that increased tryptophan metabolism toward kynurenine secondary to elevated corticosterone and TNF-α might be one of the pathohphysiological mechanisms that could explain depression like state observed in this rat model. Further, the observed attenuating effect of HP on TNF-α and corticosterone could contribute in its antidepressant effect in this animal model by other ways than their effects on tryptophan-kynurenine metabolism pathway.

Keywords: Corticosterone; Hypericum perforatum; Kyninurenine; TNF-α; Tryptophan.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of treatment with 17α-ethinylestradiol (30 µg/kg) and Hpericum Perforatum (HP; 125, 250, 500 mg/kg) on the number of squares crossed in open field test (OFT) (A) and on immobility time of forced swimming test (FST) in seconds (B) of ovariectomized rats (OVX). Correlation between body weights at the end versus immobility time in FST in the different groups (C). Data are mean±SD, number of animals=6. One way ANOVA followed by Tukey's Multiple Comparisons test: ap<0.05, compared to control sham operated group. bp<0.05 compared to OVX untreated group and cp<0.05 compared to 17α-ethinylestradiol treated group. r, Pearson's correlation coefficient.
Fig. 2
Fig. 2
Correlation between serum versus hippocampus corticosterone level in the different group. r, Pearson's correlation coefficient, P significant level.
Fig. 3
Fig. 3
Effects of treatment with 17α-ethinylestradiol (E; 30 µg/kg) and Hpericum Perforatum (HP; 125, 250, 500 mg/kg) on hippocampus. (A) Tryptophan, (B) kynurenine and (C) kynurenine/tryptophan ratio of OVX Wistar rats. Data are mean±SD, number of animals per group=6, OVX=ovariectomized. One way ANOVA followed by Tukey's Multiple Comparisons test: ap<0.05, compared to control sham operated group. bp<0.05 compared to OVX untreated group and cp<0.05 compared to 17α-ethinylestradiol treated group.

Similar articles

Cited by

References

    1. Bromberger JT, Matthews KA, Schott LL, Brockwell S, Avis NE, Kravitz HM, Everson-Rose SA, Gold EB, Sowers M, Randolph JF., Jr Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN) J Affect Disord. 2007;103:267–272. - PMC - PubMed
    1. Llaneza P, García-Portilla MP, Llaneza-Suárez D, Armott B, Pérez-López FR. Depressive disorders and the menopause transition. Maturitas. 2012;71:120–130. - PubMed
    1. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology. 1995;20:111–116. - PubMed
    1. Simen BB, Duman CH, Simen AA, Duman RS. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry. 2006;59:775–785. - PubMed
    1. Berthold-Losleben M, Himmerich H. The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. Curr Neuropharmacol. 2008;6:193–202. - PMC - PubMed